JGUA
HAE icon

John G. Ullman & Associates’s Haemonetics HAE Stock Holding History

John G. Ullman & Associates’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$926K Buy
12,350
+1,050
+9% +$67.5K 0.11% 106
2026
Q1 		$637K Sell
11,300
-2,300
-17% -$150K 0.08% 122
2025
Q4 		$1.09M Buy
13,600
+1,650
+14% +$111K 0.15% 99
2025
Q3 		$582K Buy
+11,950
New +$740K 0.08% 121

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John G. Ullman & Associates's HAE Position: Q2 2026 in Review

John G. Ullman & Associates increased its Haemonetics (HAE) stake by 9.3% in Q2 2026, buying an estimated $67.5K and bringing the position to 12,350 shares worth $926K. The position accounts for 0.11% of the portfolio, ranked #106.

John G. Ullman & Associates first reported a position in HAE in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.09M in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • John G. Ullman & Associates held 12,350 shares of Haemonetics worth $926K as of Q2 2026.
  • John G. Ullman & Associates bought 1,050 Haemonetics shares in Q2 2026, an estimated $67.5K.
  • Haemonetics made up 0.11% of John G. Ullman & Associates's portfolio in Q2 2026, its #106 holding.
  • John G. Ullman & Associates first reported a position in Haemonetics in Q3 2025 and has held it in 4 quarters since.
  • John G. Ullman & Associates's Haemonetics position peaked at $1.09M in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on John G. Ullman & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.